Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136746 | 0.92 | HPGD (0.53) | KMT2AHSD17B10MEN1ALDH1A1TSHR | |
| SCHEMBL28908599 | 0.82 | KMT2A (0.70) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL134590 | 0.77 | KMT2A (0.68) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL7542052 | 0.76 | HDAC8 (0.67) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL7542107 | 0.76 | HDAC8 (0.67) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL7548687 | 0.76 | HDAC8 (0.67) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL9847185 | 0.76 | HDAC8 (0.67) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL7424373 | 0.76 | KMT2A (0.63) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL7548208 | 0.76 | HDAC8 (0.67) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL8779372 | 0.76 | HDAC8 (0.67) | KMT2AHSD17B10MEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5159108-A | Process for preparing an antihypercalcemic agent | MERCK & CO., INC. (US) | 1992-10-27 | — | — | US | claimed |
| US-10071110-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | CHIMERIX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160303147-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE PHOSPHONATES | CHIMERIX, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2155257-B1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | CHIMERIX INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-18 | — | — | US | disclosed |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-11 | — | — | US | disclosed |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-6716825-B2 | OSTEOPOROSIS AND OTHER DISORDERS OF BONE METABOLISUM, CANCER, VIRAL INFECTIONS, AND THE LIKE. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-06 | — | — | US | disclosed |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1233770-A4 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1233770-A2 | PHOSPHONATE COMPOUNDS | The Regents of The University of California at San Diego (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001039724-A2 | PHOSPHONATE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2001-06-07 | — | — | WO | disclosed |
| US-5159108-A | Process for preparing an antihypercalcemic agent | MERCK & CO., INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5039819-A | Diphosphonate intermediate for preparing an antihypercalcemic agent | MERCK & CO., INC. (US) | 1991-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | ENPP1, ADA, ENTPD5 | KMT2A 1547/4885HSD17B10 4694/4885MEN1 1346/4885 |
| US-20160303147-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE PHOSPHONATES | SLC29A1, SLC28A1, PHOSPHO1 | KMT2A 3213/4885HSD17B10 1495/4885MEN1 1541/4885 |
| US-10071110-B2 | Phosphonate compounds | PHPT1, PHOSPHO1, PIK3CA | KMT2A 2972/4885HSD17B10 1532/4885MEN1 464/4885 |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | TYMP, ADA, DCTD | KMT2A 2595/4885HSD17B10 3803/4885MEN1 1739/4885 |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | BPGM, PPA1, INPP5D | KMT2A 2795/4885HSD17B10 3804/4885MEN1 843/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | KMT2A 2972/4885HSD17B10 1532/4885MEN1 464/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | KMT2A 2972/4885HSD17B10 1532/4885MEN1 464/4885 |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | MTAP, SAMHD1, NT5C3B | KMT2A 2617/4885HSD17B10 1043/4885MEN1 2708/4885 |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | OAT, PNPO, OTC | KMT2A 3252/4885HSD17B10 2559/4885MEN1 4608/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | KMT2A 2392/4885HSD17B10 1547/4885MEN1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.